Advertisement
Singapore markets closed
  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     
  • S&P 500

    5,313.93
    +5.80 (+0.11%)
     
  • Dow

    39,868.34
    +61.57 (+0.15%)
     
  • Nasdaq

    16,793.97
    -0.91 (-0.01%)
     
  • Bitcoin USD

    70,666.22
    +3,852.59 (+5.77%)
     
  • CMC Crypto 200

    1,533.96
    +45.41 (+3.05%)
     
  • FTSE 100

    8,419.75
    -4.45 (-0.05%)
     
  • Gold

    2,432.00
    -6.50 (-0.27%)
     
  • Crude Oil

    79.30
    -0.50 (-0.63%)
     
  • 10-Yr Bond

    4.4100
    -0.0270 (-0.61%)
     
  • Nikkei

    38,946.93
    -122.75 (-0.31%)
     
  • Hang Seng

    19,220.62
    -415.60 (-2.12%)
     
  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     
  • Jakarta Composite Index

    7,186.04
    -80.65 (-1.11%)
     
  • PSE Index

    6,633.66
    -49.12 (-0.74%)
     

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

One stock that might be an intriguing choice for investors right now is Alnylam Pharmaceuticals, Inc. ALNY. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 73 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Alnylam Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Alnylam Pharmaceuticals, Inc. Price and Consensus

Alnylam Pharmaceuticals, Inc. Price and Consensus
Alnylam Pharmaceuticals, Inc. Price and Consensus

Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote

ADVERTISEMENT

In fact, over the past month, current quarter estimates have narrowed from loss of 89 cents per share to loss of 79 cents per share, while current year estimates have narrowed from loss of $3.19 per share to loss of $2.73 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Alnylam Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research